{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:18:04Z","timestamp":1780377484335,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Mycology Case Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mmcr.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T23:24:36Z","timestamp":1611271476000},"page":"32-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-3177","authenticated-orcid":false,"given":"Cristian","family":"Deana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Vetrugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"De Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mmcr.2021.01.002_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmi.2020.07.047","article-title":"Invasive aspergillosis in patients with severe COVID-19 pneumonia","volume":"27","author":"Helleberg","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"issue":"4","key":"10.1016\/j.mmcr.2021.01.002_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02554-2020","article-title":"Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis (CAPA)","volume":"56","author":"Armstrong-James","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.mmcr.2021.01.002_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13054-020-03046-7","article-title":"Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series","volume":"24","author":"Wang","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.mmcr.2021.01.002_bib4","article-title":"REINMUN-COVID group. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study","author":"Galv\u00e1n-Rom\u00e1n","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.mmcr.2021.01.002_bib5","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.mmcr.2021.01.002_bib6","article-title":"Comparative survival analysis of immunomodulatory therapy for COVID-19 \u2018cytokine storm\u2019","author":"Narain","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.mmcr.2021.01.002_bib7","article-title":"The COVID-19 pandemic: is our medicine still evidence-based?","author":"Deana","year":"2020","journal-title":"Ir. J. Med. Sci."},{"issue":"9","key":"10.1016\/j.mmcr.2021.01.002_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/17476348.2020.1778470","article-title":"Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2","volume":"14","author":"Robba","year":"2020","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.mmcr.2021.01.002_bib9","first-page":"m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.mmcr.2021.01.002_bib10","doi-asserted-by":"crossref","first-page":"558898","DOI":"10.3389\/fimmu.2020.558898","article-title":"COVID-19: in the eye of the cytokine storm","volume":"11","author":"de la Rica","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mmcr.2021.01.002_bib11","article-title":"IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections","author":"Kimmig","year":"2020","journal-title":"medRxiv. [Preprint]"},{"key":"10.1016\/j.mmcr.2021.01.002_bib12","first-page":"1","article-title":"Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature","volume":"14","author":"Bernardo","year":"2020","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.mmcr.2021.01.002_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s13054-020-03307-5","article-title":"No time for pending confirmation of invasive fungal disease in critically ill COVID-19 patients\u2014think empirical treatment","volume":"24","author":"Bienvenu","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.mmcr.2021.01.002_bib14","article-title":"Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - a case report","author":"Prattes","year":"2020","journal-title":"Med. Mycol. Case Rep."}],"container-title":["Medical Mycology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753921000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753921000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:03:13Z","timestamp":1761933793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211753921000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"alternative-id":["S2211753921000026"],"URL":"https:\/\/doi.org\/10.1016\/j.mmcr.2021.01.002","relation":{},"ISSN":["2211-7539"],"issn-type":[{"value":"2211-7539","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?","name":"articletitle","label":"Article Title"},{"value":"Medical Mycology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mmcr.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.","name":"copyright","label":"Copyright"}]}}